Mats C. Højbjerg Lassen, MD
@matslassen
Followers
261
Following
456
Media
41
Statuses
287
Fulbright research fellow @BrighamWomens @harvardmed | PhD @HGHHjerte @CTCPR_ - pragmatic clinical trials and cardiac imaging | MSc Clinical Trials @Oxford_ndph
København, Danmark
Joined May 2018
Thanks @hvanspall! It was such an honor for us all that you and so many of our friends and collaborators decided to join the @CTCPR_ annual ESC dinner to celebrate all the work of the incredible team and mentees 🙏 @mvaduganathan @rkwadhera @FudimMarat @DLBHATTMD @robmentz &more
I was so happy to celebrate @TorBiering’s outstanding presentations & sim pubs at #ESCcongress! Amazing to carve out a career path that is uniquely one’s own, while pouring in so much effort into mentees. Proud of you, friend. 👏 @CTCPR_
1
6
23
I was so happy to celebrate @TorBiering’s outstanding presentations & sim pubs at #ESCcongress! Amazing to carve out a career path that is uniquely one’s own, while pouring in so much effort into mentees. Proud of you, friend. 👏 @CTCPR_
📌 Most viewed this week from JAMA Cardiology: Among older adults, high-dose influenza vaccine modestly reduced cardiorespiratory and cardiovascular hospitalizations compared to standard-dose vaccine. https://t.co/kh52CuGjuC
0
6
33
I’m more than proud to lead a team of the most talented researchers I have ever met 👩🎓🧑🏽🎓Congratulations to the whole team with this accomplishment 👏 It’s an honor to work with and learn from you all 🙏 @CTCPR_ for the win 🌟
🚨 An extraordinary achievement from all the @CTCPR_ researchers at ESC! Our researchers simultaneously published 13 papers across leading journals, showcasing some of the latest breakthroughs in cardiology. These publications include: · 3 in The New England Journal of Medicine
2
9
36
New Paradigm: Vaccination for CV Health #CVprev #ESCCongress
#DANFLU2: High-dose flu vaccine associated w reduction in cardiorespiratory hospitalization (exploratory) https://t.co/iIUDttqV33
#DANRSV: RSV vaccine reduces cardiorespiratory hospitalizations https://t.co/wmS51FnAGx
0
17
45
.@TorBiering has entirely changed the game & transformed the clinical trial landscape! #DANFLU2 #GALFLU #DANRSV provide a glimpse at the possibilities of randomizing at scale & addressing fundamental unanswered questions. Hats off to @niklasdj1 @matslassen & entire @CTCPR_ team
1
12
41
Incredible trifecta by #JohnOstrominski in @JACCJournals w #ESCCongress John is a one-of-a-kind talent, blending his joint CV & obesity fellowships, to lead a career in #CKM investigation. One to watch! 🚀 https://t.co/8u5ebXU5q7
https://t.co/3O4njKwSwk
https://t.co/kPC5KFpX25
1
20
87
Proud to have contributed to this work! 🙏
🚨 An extraordinary achievement from all the @CTCPR_ researchers at ESC! Our researchers simultaneously published 13 papers across leading journals, showcasing some of the latest breakthroughs in cardiology. These publications include: · 3 in The New England Journal of Medicine
0
0
5
DANFLU-2 presented by @TorBiering at #ESCCongress today! Monumental 3-year effort by everyone involved! Out now in @NEJM: https://t.co/m2Hjz4ua2d No sig ⬇️ in hosp for composite of flu or pneumonia, but lower incidence of hosp for cardio-resp disease and flu alone ♥️🫁
2
12
21
🇩🇰 Saturday @escardio #ESCCongress2025 Part 1: DAN-RSV RSVpreF vaccine virtually eliminates the need of hospitalization for RSV in elderly people & reduces total numbers of hospitalisation for respirotory disease. @matslassen @TorBiering @CTCPR_
https://t.co/JtynmYLtjk
2
6
15
DAN-RSV trial effects on CV outcomes now out in @JAMA_current 🫀 👴👵 131K older adults randomized 1:1 to RSVpref vaccine or no vaccine RSVpreF vaccine reduced all-cause cardiorespiratory hospitalizations by 9.9% 🫀🫁🏥 @CTCPR_ @TorBiering
Among adults ≥60 years, the RSVpreF vaccine reduced all-cause cardiorespiratory hospitalizations but showed no significant effect on isolated cardiovascular events, finds this prespecified analysis of the DAN-RSV trial. 🧵 #ESCCongress #WCCardio
https://t.co/elz3hYfm9E
0
7
14
🏥 Take-home: Among older adults, RSVpreF vaccination substantially reduces severe RSV disease & hospitalization burden, with a reassuring safety profile. 🌍 Real-world, pragmatic design supports broad public health impact. #ESCCongress #RSV #ClinicalTrials
0
0
0
💡 Results (ITT, n=131,276): 🔹 RSV hospitalization: 3 vs 18 events → 83% VE (95%CI 43–97) 🔹 RSV LRTD hospitalization: 1 vs 12 events → 92% VE (95%CI 44–100) 🔹 All-cause RTD hospitalization: 284 vs 335 events → 15% VE (95%CI 0.5–28) 🔹 SAEs: similar across groups
1
0
0
📊 Methods: 🔹 Individually randomized, open-label, registry-based trial 🔹 131,379 adults ≥60y randomized 1:1 to RSVpreF 💉 vs no vaccine 🔹 Follow-up: 14d post-study visit → May 2025 🔹 Primary endpoint: RSV-related respiratory hospitalization
1
0
0
👵👴 In a pragmatic 🇩🇰 RCT of 131k adults ≥60y, RSVpreF vaccine 💉 reduced: ➡️ RSV hosp by 83% ➡️ LRTD hosp by 92% ➡️ All-cause RTD hosp by 15% Safety ✅ Presented today at #ESCCongress 🫀🫁 Out now in @NEJM
https://t.co/bQfLBQy9P5
@TorBiering @CTCPR_
2
16
35
Proud to have our DAN-RSV trial main results out in @NEJM
Presented at #ESCCongress: In the DAN-RSV phase 4 trial, the RSV vaccine reduced the incidence of hospitalization for RSV-related respiratory tract disease as compared with no vaccine among adults 60 years of age or older. Full trial results: https://t.co/DKXUNsL4Ks
@escardio
0
11
30
Among adults ≥60 years, the RSVpreF vaccine reduced all-cause cardiorespiratory hospitalizations but showed no significant effect on isolated cardiovascular events, finds this prespecified analysis of the DAN-RSV trial. 🧵 #ESCCongress #WCCardio
https://t.co/elz3hYfm9E
2
17
45
Presented at #ESCCongress: In the DAN-RSV phase 4 trial, the RSV vaccine reduced the incidence of hospitalization for RSV-related respiratory tract disease as compared with no vaccine among adults 60 years of age or older. Full trial results: https://t.co/DKXUNsL4Ks
@escardio
4
30
67
🚨 Coming up Saturday at #ESCCongress 🚨 Main results from the DAN-RSV trial 👵👴 (n=131,379; age ≥60) 💉 RSVpreF vaccine vs no vaccine 🏥 Outcomes: RSV-related and all-cause hospitalizations Big news for RSV prevention - 👀 out for simpubs! design 📄: https://t.co/W8JZZdtTEa
1
11
24
The countdown is on! DANFLU-2 will be presented at #ESCCongress on Saturday! 332,438 adults ≥65 years 👵👴 High-dose vs standard-dose influenza vaccine 💉 Severe outcomes: hospitalizations and deaths 🏥☠️ Design paper: https://t.co/BcqEe1xT8I Look out for simpubs! 👀
3
17
38
2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on Adult Immunizations as Part of Cardiovascular Care More to come: DANFLU-2 & DAN-RSV from @matslassen @TorBiering @niklasdj1 @CTCPR_ Next Saturday #ESCCongress 2025 https://t.co/UbRTNSVRjQ
1
7
14